CDC73
Gene Ontology Biological Process
- mRNA 3'-end processing [IMP]
- negative regulation of DNA recombination [IMP]
- positive regulation of histone H3-K36 trimethylation [IMP]
- positive regulation of phosphorylation of RNA polymerase II C-terminal domain serine 2 residues [IMP]
- positive regulation of transcription elongation from RNA polymerase I promoter [IDA]
- positive regulation of transcription elongation from RNA polymerase II promoter [IMP]
- recruitment of 3'-end processing factors to RNA polymerase II holoenzyme complex [IMP]
- regulation of histone H2B conserved C-terminal lysine ubiquitination [IDA]
- regulation of transcription-coupled nucleotide-excision repair [IGI]
- transcription elongation from RNA polymerase I promoter [IMP]
- transcription elongation from RNA polymerase II promoter [IGI]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
YKU70
Gene Ontology Biological Process
- chromatin assembly or disassembly [IDA]
- chromatin silencing [IDA, IMP]
- chromatin silencing at silent mating-type cassette [IGI, IMP]
- double-strand break repair via break-induced replication [IGI, IMP]
- double-strand break repair via homologous recombination [IMP]
- double-strand break repair via nonhomologous end joining [IMP]
- mitochondrial double-strand break repair via homologous recombination [IMP]
- telomere maintenance [IMP]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Negative Genetic
Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores.
Publication
A Network of Conserved Synthetic Lethal Interactions for Exploration of Precision Cancer Therapy.
An emerging therapeutic strategy for cancer is to induce selective lethality in a tumor by exploiting interactions between its driving mutations and specific drug targets. Here we use a multi-species approach to develop a resource of synthetic lethal interactions relevant to cancer therapy. First, we screen in yeast ∼169,000 potential interactions among orthologs of human tumor suppressor genes (TSG) and ... [more]
Quantitative Score
- -11.83 [Confidence Score]
Throughput
- High Throughput
Ontology Terms
- phenotype: colony size (APO:0000063)
Additional Notes
- Untreated conditions. SGA was used to score genetic interactions based on the colony size of double versus single mutants. Genetic interactions were considered significant if they had an S score >= 2.0 for positive interactions (epistatic or suppressor interactions) and S score <= -2.5 for negative interactions (synthetic sick/lethal interactions).
Related interactions
| Interaction | Experimental Evidence Code | Dataset | Throughput | Score | Curated By | Notes |
|---|---|---|---|---|---|---|
| YKU70 CDC73 | Negative Genetic Negative Genetic Mutations/deletions in separate genes, each of which alone causes a minimal phenotype, but when combined in the same cell results in a more severe fitness defect or lethality under a given condition. This term is reserved for high or low throughput studies with scores. | High | -4.1481 | BioGRID | 219164 | |
| CDC73 YKU70 | Phenotypic Enhancement Phenotypic Enhancement A genetic interaction is inferred when mutation or overexpression of one gene results in enhancement of any phenotype (other than lethality/growth defect) associated with mutation or over expression of another gene. | Low | - | BioGRID | 2598580 |
Curated By
- BioGRID